SUMMARY: Via Business Insider “CEOs have for decades chanted the mantra of shareholder supremacy and placed cost-cutting and short-term profits above all else. That mindset, however, just might be changing.” It might be changing in other industries but within pharma, the mindset is still “short term balance sheet”.Read more
- Pharmacy benefit managers said rebates paid by drug companies to PBMs, sometimes called “middlemen,” are “not secret or hidden payments”
- Executives blamed high drug prices on the drugmakers and their pursuit of profits.
- U.S. Healthcare Spending Reaches $420M Per Hour, On Track to Hit $12 Trillion by 2040.
- 62 health care CEOs made a combined $1.1 billion in 2018 when calculating the actual value of cashed-out stock.
- In the meantime Republicans are warning drug companies not to cooperate with probes into drug pricing.
IN SUMMARY: When the list price of a drug goes up but the net price goes down there is something dreadfully wrong with our healthcare system. The hearings, before Congress yesterday, were meant to convey to voters that “we’re doing something” but patients are not likely to see any benefits from ANY Congressional hearings until the SYSTEM is questioned.Continue reading
KEY IDEA: Today some pharma CEO’s will go to Congressional Hill to answer questions about high drug prices. Politicians are conducting this charade because they want to give voters the idea that “they care” and that they are doing something. What won’t be discussed are the real reasons American healthcare is the most expensive in the world with poor results.Continue reading
KEY TAKEAWAY: If you ever doubt that there is a leadership void within pharma just look at the current crop of CEO’s who will do and say anything to protect their jobs (and paychecks) and appease the people on Wall Street. Continue reading
-Pharma CEO’s should not be evaluated on the company’s stock price alone.
-When Wall Street wins patients usually lose.
-Mr Merck was right, putting patients first will lead to profits. Continue reading